Trial Profile
Effect of Natalizumab (Tysabri) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 06 Sep 2011 Actual end date November 2010 added as reported by ClinicalTrials.gov.
- 06 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.